Filtered By:
Drug: Invokana
Procedure: Heart Transplant
Therapy: Dialysis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
ConclusionModel results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - December 2, 2020 Category: Endocrinology Source Type: research
Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
ConclusionCREDEM-DKD is an important new tool in the evaluation of treatment interventions in the DKD population.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - September 14, 2020 Category: Endocrinology Source Type: research
